Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 2 pseudogene 1 (HMGB2P1) is classified as a pseudogene—a genomic sequence similar to the high mobility group box 2 (HMGB2) gene, but lacking protein-coding capability and evidence for direct transcription or translation[6]. Pseudogenes often arise from duplication or retrotransposition events, and typically do not produce functional proteins. Some pseudogenes can have regulatory effects on their parent gene via RNA-mediated mechanisms, but no such function is documented for HMGB2P1[2][4]. HMGB2P1 should not be confused with HMGB2, which is a functional chromatin-associated protein involved in transcription and DNA repair, and is a potential therapeutic target[3]. No drugs, disease associations, or biomarker applications have been reported for HMGB2P1, and it is not described as a receptor, enzyme, or functional target in human physiology or pharmacology[6]. In summary, HMGB2P1 is a non-functional pseudogene with no established biological or therapeutic role. Use of HMGB2P1 as a biomedical target is incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 2 pseudogene 1 (HMGB2P1).